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Abstract
Background: Alpha-1 antitrypsin deficiency is a heritable genetic condition that is largely
underdiagnosed and has been estimated to affect 1 out of every 5,000-7,000 people in North
America. The condition is characterized by a decrease in the production or activity of the alpha-1
antitrypsin protein, increasing risk for chronic lung or liver inflammation, that may lead to
disease. Currently, there is no cure for the condition and augmentation therapy, which replaces
the lost protein, has shown mixed results, meaning preventive measures taken by the patient are a
large component of the prescribed treatment. Thus, patients with the condition are strongly
encouraged to quit smoking, reduce drinking, avoid occupations or areas that have high levels of
particulate matter or toxic air pollutants as well as maintain active vaccinations against lung and
liver infections like pneumonia, hepatitis A and B, and the flu to prevent complications from the
condition.

Objectives: This study aims to 1) Access the associations between adherence to the AlphaNet
disease management and prevention program and the prophylactic measures that are encouraged
by the program and; 2) determine if any of these associations are a result of demographic and
health differences between individuals who are adherent ADMAPP and those who are not.

Methods: This is a cross-sectional study of 3,526 individuals with alpha-1 antitrypsin deficiency
who answered a questionnaire administered by AlphaNet from May 29th 2008 to February 14th
2015 as part of the Alpha-1 Antitrypsin Management and Prevention Program. This study
focused on questions related to adherence to the program and prophylactic measures taken by the
individual that are encouraged by the literature given out by the program. Only individuals who
2

answered questions about their adherence to the program were included in this current study.
Demographic differences between the two stratified populations and an index for comorbidities
were used for logistic regression analysis.

Results: After adjustment for sex, age, income, and comorbidies, compared with individuals who
self-reported as being non-adherent to the disease management and prevention program, adherent
individuals were more likely to be comfortable with their knowledge of the disease (ORadj=4.95,
95% CI: 3.24-7.57), have read any part of the literature provided by the program (ORadj=6.44,
95% CI: 5.45-7.62), and use augmentation therapy (ORadj=2.08, 95% CI: 1.53-2.82). These
individuals were also more likely to be vaccinated for the flu (ORadj=1.34, 95% CI: 1.08-1.68),
Hepatitis A (ORadj=1.41, 95% CI: 1.20-1.66), and Hepatitis B (ORadj=1.62, 95% CI: 1.37-1.91),
as well as exercise (ORadj=2.07, 95% CI: 1.74-2.47), while being less likely to be active smokers
(ORadj=0.47, CI: 0.31-0.70).

Conclusions: This study suggests that AlphaNet program may be a useful tool for informing and
improving preventive measures taken by individuals with alpha-1 antitrypsin deficiency.
Individuals who self-reported their percent adherence to the program as being nonzero were
more likely to be informed about their condition and taking preventive measures, such as
smoking cessation, getting vaccinated for conditions that could magnify the effects of AATD,
and increases in self-reported exercise. Future studies are needed to show causality and
improvement in participant outcomes such as mortality and quality of life.
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Introduction
Alpha-1 antitrypsin deficiency (ATTD) was first described in 1963 by Carl-Bertil Laurell and
Sten Eriksson who observed low levels of the alpha-1 antitrypsin (ATT) protein associated with
the symptoms of emphysema [1]. This discovery, coupled with the association of ATTD with
liver cirrhosis has led to a recognition as ATTD as being a predisposing factor for the
development of liver disease and emphysema. While the condition has been identified for over
50 years, our understanding of the disease as well as the information concerning its prevalence is
limited.

ATTD is a heritable condition that, as its name suggests, is a result of an individual having lower
levels of the alpha-1 antitrypsin (ATT) protein. Lower levels of this protein have been linked to
numerous diseases; the majority of which are related to impaired lung function and liver disease
[2]. Currently there are no cures for ATTD, but several treatment options are available, most of
which are the same as the ones used to treat chronic obstructive pulmonary disease (COPD) [3].
Augmentation therapy, where intravenous AAT is administered to patients, usually on a weekly
basis, as well as gene therapy have also been explored as possible treatment options [3, 4], but
the efficacy of these treatments is debatable; there is a lack of well-designed randomized clinical
trials, among other things [5-7].

To help patients, families of patients, and healthcare providers navigate the wealth of
information on AATD, individuals from AlphaNet, a not-for-profit organization founded in
4

1995, have developed the Alpha-1 Disease Management and Prevention Program (ADMAPP).
The program provides support as well as education on the disease [8]. A large part of the
education component is devoted to prophylactic measures that individuals with ATTD can take
to help decrease the risk of further disease complications.

Since there is no active cure for ATTD, preventive measures are emphasized, such as smoking
cessation and vaccination for certain diseases, all of which are part of the ADMAPP program.
Therefore, the purpose of this analysis was to: 1) access the associations between adherence to
the AlphaNet disease management and prevention program and the prophylactic measures that
are encouraged by the program and; 2) determine if any of these associations are a result of
demographic and health differences between individuals who are ADMAPP adherent and those
who are not.
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Literature Review
The following review of literature is a summary of current scientific knowledge and
understanding of ATTD. It is a collection of knowledge from the molecular mechanics and
genetics perspective, as well as a larger, epidemiological view of the topic. The works cited are a
collection of peer-reviewed articles found on scientific literature search engines such as PubMed.
The purpose of this review is to summarize the information available on ATTD that is applicable
to this study and is not an exhaustive review of all the literature available.

Genetics and mechanism of action
AATD is an inherited autosomal codominant genetic condition following the Mendelian pattern
of inheritance [9]. The condition is a result of a single nucleotide polymorphism (SNP) in the
gene that codes for the ATT protein. These SNPs have the potential to change the amino acid
composition of the protein and therefore the charge of the protein. The changes in charge alter
the speed at which the proteins migrate on gel electrophoresis, which is used to characterize the
specific phenotype of an individuals with ATTD [9]. The phenotypes are labeled alphabetically
with the A allele having the highest rate of migration, while the more commonly observed Z
allele having the slowest, and the M allele having the normal speed.[9, 10]. For clarity, the
remainder of this paper will refer to the specific alleles using the common nomenclature, which
is PI* (standing for protease inhibitor) followed by the allele (i.e. PI*ZZ for the homozygous Z
allele phenotype).
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The specific phenotype that a patient with ATTD has is clinically significant, as each is
correlated with the degree of severity of the condition [10]. For instance, the PI*SZ and PI*ZZ
mutations reduce ATT levels by 25% and 15% of normal, respectively [11]. This is in contrast to
the more rare PI*NullNull variant, which results in the total absence of ATT due to
transcriptional or translational errors that create a protein that is ultimately degraded [9, 11].

Normally, the ATT protein functions as a serine protease inhibitor, with the most notable
substrate being neutrophil elastase. Briefly, when immune cells known as neutrophils are
recruited to sites of inflammation they release elastase, an enzyme with broad substrate reaction
activity capable of attacking a number of host proteins as well as numerous xenobiotics like
bacteria or chemicals found in smoke. The release of elastase in response to inflammation is a
protective mechanism by the body, as the enzyme has numerous beneficial actions such as
impairing phagocytosis of bacterial pathogens [9]. ATT helps balance the protective effects of
the elastase while limiting the damage to the host.

In individuals with ATTD, levels of ATT are decreased resulting in increased host damage.
Importantly, the phenotype of an individual has been found to be the best determinant of ATT
level variation [12]. In addition to decreased levels of ATT, the ATT present in ATTD
individuals may be dysfunctional and less capable of antiprotease activity [10].

Prevalence
The presence of ATTD varies widely among different populations [13], with the largest presence
being detected in groups with European ancestry, particularly in the Scandinavia regions of
7

Europe [3, 14]. In addition to variable prevalence of the condition, the distribution of specific
alleles also varies within populations [13]. This becomes especially important in North America
where the mixed descendent population creates even more variability [15]. Prevalence
approximations of ATTD in North American, especially the United States, are hindered by this
fact, but it has been estimated to be as high as 1 out of every 5,000-7,000 individuals in North
America for the non-PI*MM (normal) phenotypes [16].

The figures for ATTD prevalence are further complicated by the lack of testing for the condition.
Recent findings showing an increased prevalence in a wide array of countries indicate the
impression of ATTD being a relatively rare disease may be a function of lack of testing. In
addition, it has been estimated that 10-35% of individuals with certain alleles may not ever
present with clinical symptoms, further decreasing chances of the condition being detected
[3].These observations suggest that the condition is not rare, but rather rarely diagnosed [17].

Disease Risk
The majority of diseases associated with AATD are a result of pulmonary impairment (e.g.,
COPD, bronchiectasis), with a smaller proportion of patients having hepatic (e.g., cirrhosis,
hepatoma) and vasculitis manifestations of the condition [2, 3, 18, 19]. Several other disease,
such as coeliac disease and certain cancers, have been suggested as well, but the associations
remains unclear [18]. While the specific mechanisms of the disease progression out of the scope
of this study, it is important to note the systems affected by AATD.
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Lung disease in patients with AATD usually manifests as emphysema or COPD and generally
begins in early adulthood. The development of these diseases are often exacerbated by the
presence of compounding factors such as smoking or infection [20]. Lung injury is a result of
decreased levels of ATT in the lungs, which leads to unchallenged proteolytic damage to the
lung tissue [3, 19]. Risk of lung disease is strongly correlated with the variant of ATTD, with
PI*SZ, PI*ZZ, and PI*NullNull being the most significantly at risk [18].

While ATTD manifests as liver disease less frequently than lung disease, it can lead to serious
liver dysfunction in some patients. Liver complications begin as hepatitis (inflammation of the
liver) which can lead to liver cirrhosis. Unlike lung disease, the mechanism resulting in liver
disease as a result of ATTD is not related to the loss of inhibitory functionality, but instead is a
result of protein accumulation in the hepatocytes [18, 19]. In individuals with the PI*ZZ, and less
frequently, the PI*SZ variant of ATTD, the amino acid substitution in the ATT protein causes
the proteins to spontaneously polymerize, or bind together [19]. The polymerization of the
protein prevents its secretion, leading to cellular inflammation and a further decrease in
circulating ATT levels [18].

It is not surprising that all of the prophylactic measures suggested to ATTD patients focus on
lung and liver injury prevention. ATTD patients are strongly encouraged to quit smoking, reduce
drinking, avoid occupations or areas that have high levels of particulate matter or toxic air
pollutants as well as maintain active vaccinations against lung and liver infections like
pneumonia, hepatitis A and B, and the flu [20, 21]. With an impaired ability to respond to
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xenobiotic insults, it is important that ATTD patients prevent unnecessary stress on the lungs or
liver.
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Methodology
Study population
This study uses data gathered from an introductory questionnaire that individuals with ATTD in
the AlphaNet system completed that has been previously described elsewhere [22]. The data set
is a collection of qualitative, self-reported, questionnaire responses containing information from
4,747 unique individuals, with missing entry frequency varying between a few hundred to a few
thousand. The answer date of the questionnaire ranges from May 2008 to February 2015 and
contains up to 178 responses per individual. This data set includes basic demographic
information (e.g. sex, race, marital status, income level), medical history (e.g. specific ATTD
genetic variant, current medical conditions) and lifestyle choices (e.g. smoking, drinking, and
exercise habits).

The study population was determined by the response to two questions in the questionnaire
regarding adherence to the ADMAPP. Participants were ask if they currently followed the
guidelines of ADMAPP as well as their estimated percentage of compliance. Any participants
who responded yes or had a percent compliance as being nonzero was considered adherent,
while participants who responded no or had a percent compliance of zero was considered nonadherent. After this classification process, 1,221 of the participants had missing adherence
information and were therefore excluded from the study, leaving a final study population of
3,526, which was further stratified into two groups based on their self-reported compliance with
the program (Figure 1).
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Figure 1. Flowchart of the study population.

Study Design
This is a cross sectional study aimed at identifying, assessing, and analyzing any associations
found related to individuals with ATTD being compliant with the ADMAPP. The outcome of
interest was on the differences in the preventive lifestyle choices between the two groups (i.e.
smoking, drinking, vaccinations), health status (i.e. BMI, perceived health), and knowledge of
the disease.
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Variables
All of the variables used in this study were generated from self-reported data. Using this selfreported information, the following variables were used in the analysis: sex, age, race, variant of
AATD, the reason they were originally tested and diagnosed for AATD, comfort level with
disease knowledge, use of augmentation therapy, smoking status, drinking habits, vaccinations,
BMI, perceived weight, fitness level, and health, exercise habits, heath care visits, and
emergency service visits.

The outcomes variables were grouped into three categorized (Disease knowledge and treatment,
exacerbating and prophylactic factors, health and health perception) based on similarities in
measured outcome. Disease knowledge and treatment included self-reported comfort with
current disease knowledge, as well as whether they had read any part of the BFRG and if the
participant was currently using any kind of augmentation therapy. Exacerbating and prophylactic
factors included current smoking status, drinking habits, as well as whether the participant had
received certain vaccinations. Health and health perception included exercise habits, body mass
index (BMI), health provider visits, emergency service utilization, and perceptions on various
aspects the participant health.

The body mass index was calculated by dividing the weight by the square of the height and
multiplying by a conversion factor of 703, per CDC guidelines [23]. The age of the participant at
the time of survey completion was calculated by taking the difference between the date of birth
and date the questionnaire was answered. Originally the exercise habits of individuals were
broken up based on the location and regularity of the exercise. These variables were combined so
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indication of exercise at any location, regardless of regularity, was categorized as an affirmative
answer.

Missing and Nonsensical Data
This data set was not complete for all respondents. In order to remain transparent about this
limitation, descriptive variables were reported for the individuals who were missing information
for ADMAPP adherence. Currently, there is no consensus on how to statistically test for whether
or not missing data is missing at random or not, which was assumed in this study. In an attempt
to validate this assumption, statistical analysis was performed on differences between the study
population and the missing population using various demographic and outcome variables.

To help with the issue of erroneous or nonsensical data points, several decisions regarding these
data points were made, all of which are reported below.

Any variable that contained a response recorded as being unknown, was reclassified as being
missing unless that was an option on the questionnaire. For questions that had sub-questions
based on the answer to the original, the original answer was considered correct. For example, if
an individual answered no to “Have you ever smoked cigarettes?” but had responses recorded for
“How many years did you have you smoked?” or “Are you still smoking?” the responses
following the original question of “Have you ever smoked cigarettes?” were marked as missing.
All instances where the inch portion of a person’s height were reported as being “12” were
marked as missing, ultimately resulting in missing information for BMI. Finally, if self-reported
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ADMAPP compliance was reported as 0 then those individuals were recoded as being noncompliant, while any compliance above 0 was considered to be compliant.

Charlson Comorbidity Index
In order to ensure differences between the two groups was not due to individuals who had more
serious medical conditions being unequally distributed between the groups, the Charlson
Comorbidity Index (CCI) was used. Briefly, the CCI utilizes categories of comorbidities with
associated weight (Table 1) based on the risk of mortality. Mortality risk increases proportionally
with the CCI score [24]. For the CCI calculations, missing or negative answers for each
condition were given a score of 0, which is why there are no missing observations missing this
demographic characteristic.
Table 1. The Charlson Comorbidity Index (CCI) Scoring System
Weight/Score
1

2

3
6

Condition
Diabetes
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Dementia or Alzheimer’s
Connective tissue disease
Ulcer disease
Mild liver disease
Paralysis of arms and/or legs
Moderate or severe kidney disease
Any tumor or cancer
Leukemia
Lymphoma
Moderate or severe liver disease
AIDS
Metastatic cancer
15

ADMAPP and the Big Fat Reference Guide (BFRG)
The Big Fat Reference Guide (BFRG) is a free resource provided by the AlphaNet. It is a
comprehensive guide meant for patients with ATTD, their families, and medical providers and is
one of the main components of the ADMAPP. Adherence with the ADMAPP is largely
associated with complying with the suggestions in the BFRG. Unfortunately, the question
pertaining to ADMAPP adherence did not specifically as what parts of the program the
individual was compliant with, but merely an estimation of overall compliance.

Statistical analysis
Data were analyzed using SAS software, Version 8 of the SAS System for Windows.
Frequencies and percentages were reported for categorical variables for the entire population as
well as the subgroups within the population and were compared using chi-square tests.
Continuous variables were reported as means and standards deviations; t-tests were used for
comparisons. P values were reported for both continuous and categorical variables, with the
significance threshold being a P value less than 0.05.

Crude odds ratios and the respective 95% confidence intervals were calculated for the variables
of interest using the Proc Freq function. Adjusted odds ratios were calculated using the Proc
Logistic function, controlling for age, sex, CCI, and income. Covariates were chosen based on
differences in population demographics as well as potential for confounding. These covariates
were then analyzed for model inclusion using a stepwise technique described elsewhere [25], the
results of which are summarized in Table 2. While there was a statistically significant difference
16

in race between the stratified groups, the populations were almost entirely homogenous (white),
therefore decided that the variable would not help our predictions. The study protocol was
approved by the the Institutional Review Board at the University of Kentucky.
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Results
Sample Overview
The characteristics of the total sample and sample stratified by ADMAPP compliancy as well as
missing compliancy information is presented in Table 1. Overall the sample was a fairly evenly
split between male and female, with no statistical differences in age, reason for original
diagnosis, or the CCI between the ADMAPP compliancy stratified populations. Significant
differences were observed in marital status, race, income, and specific AATD variant of the
participant. By comparing the stratified populations we found majority of the selected variables
were statistically different (Table 6). In addition, a choropleth map showing the number of
participants per state is displayed in Figure 1, showing the geographical diversity of the
population.

Disease Knowledge and Treatment
Initial analysis showed statistical differences between the stratified populations in all three of the
disease knowledge and treatment outcome variables (Table 4). These variables included selfreported comfort with knowledge of the disease, whether or not they had ever read any part of
the BFRG, and if they were currently using any kind of augmentation therapy. Adjustment for
possible cofounders using logistic regression (Table 5) revealed individuals compliant with
ADMAPP were more likely to feel comfortable about their knowledge of the disease
(ORadj=4.95, 95% CI: 3.24-7.57), have read any part of the BFRG (ORadj=6.44, 95% CI: 5.45-
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7.62), and twice as likely to be currently using augmentation therapy (ORadj=2.08, 95% CI: 1.532.82).

Exacerbating and Prophylactic Factors
Initial analysis showed statistically significant differences for almost all of the exacerbating and
preventive factors (Table 4). Prior to adjustment, significant increases in odds were observed in
drinking status as well as all vaccination rates, while showing a decreased odds of smoking
(Table 5). After adjusting for possible confounding, the increase in drinking status and
pneumonia vaccination rates were no longer statistically significant. ADMAPP adherence was
found to have a statistically significant, but marginal effect, on vaccination rates for flu in the last
year (ORadj=1.34, 95% CI: 1.08-1.68), Hepatitis A (ORadj=1.41, 95% CI: 1.20-1.66), and
Hepatitis B (ORadj=1.62, 95% CI: 1.37-1.91). Most notably, odds of ADMAPP adherent
participants still being a smoker were greatly decreased (ORadj=0.47, CI: 0.31-0.70).

Health and Health Perception
Prior to logistic regression adjustment (Table 5), of all the health and health perception outcome
variables examined, only exercise status (OR=2.21, 95% CI: 1.89-2.59), self-reported perception
of weight (About Right vs Overweight, OR=1.17, 95% CI: 1.02-1.35), self-reported perception
of physical health (Pretty fit/Getting fit/Very fit vs. Out of Shape, OR=1.68, 95% CI: 1.47-1.93),
self-reported perception of overall health (Excellent/Good vs Fair/Poor, OR=1.32, 95% CI: 1.151.51), if participant saw a physician other than the ones listed (OR=1.29, 95% CI:1.12-1.47), and
if a participant had any unscheduled physician visits (OR=1.16, 95% CI: 1.01-1.33) were
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statistically significant. After adjustment, only exercise status (ORadj=2.07, 95% CI: 1.74-2.47),
self-reported perception of physical health (ORadj=1.66, 95% CI: 1.43-1.94) if participant saw a
physician other than the ones listed (ORadj=1.28, 95% CI:1.10-1.50), and if a participant had any
unscheduled physician visits (ORadj=1.27, 95% CI: 1.08-1.48).
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Discussion
Missing Completely at Random Assumption
Missing information was a significant problem in this study, with 25.72% of subjects available in
the dataset having no information on ADMAPP adherence. While there is no consensus on the
appropriate way to determine when missing data is considered missing completely at random
(MCAR), it is an important consideration for this study. To address this issue, demographic and
outcome variables were arbitrarily selected and compared between the population with
ADMAPP adherence information and the missing population.

After analysis, 11 of the 16 demographic characteristics and outcomes examined (Table 6) were
found to be significantly different between the two populations. While these findings suggest the
data is not MCAR there is a large number of missing information within the missing population.
Of the 11 variables found to significantly different, 9 had a majority of missing observations.
Taken together, these findings make it difficult to conclude the nature of the missing data.

ADMAPP Adherent Participants are More Informed About AATD
Self-reported comfort with knowledge on ATTD, as well as utilization of the BFRG were
associated with the largest odds ratio increase of all the outcome variables examined. The
information contained within the BFRG is extensive, covering a multitude of topics that are
related to ATTD and the observed increase in utilization is substantial. The guide itself is the
largest part of the ADMAPP program so these results suggest that individuals are reading the
guide and are retaining information from it, which may translate into prophylactic behavioral
21

changes. These results must be interpreted cautiously though, as this is not a validated measure
of change in participant knowledge and is relative to the person answering the question. It does
not measure whether or not the knowledge is correct, merely whether or not they feel
comfortable with their knowledge.

Physician and Emergency Medical Service Utilization
The interpretation of the overall physician and emergency medical services utilization is difficult
for this data set and must be done cautiously. For the purposes of this analysis, health provider
visits (primary care, lung or liver specialist, other MD) were considered preventive measures.
This was done because the BRFG suggests annual or biannual visits to a primary care physician
and other physicians visits as necessary, which is the rational for doing logistic regression with
physician visits being categorized as a binary outcome (did or did not use). It could be
understandably argued that these same outcomes could be a negative indication.

Interestingly, in unadjusted analysis (Table 4), the average number of primary care visits was
higher in the non-adherent group, although the increase is not clinically significant. Once the
primary care visits were re-categorized as a binary variable, this difference was lost, leaving only
a slight increase in odds of “other” physician utilization. Considering the large number of
physician specialties completely unrelated to ATTD, it is impossible to confidently draw any
conclusions on the implications of these findings.
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Prophylactic Measures Associated with ADMAPP Adherence
Since there is currently no cure for AATD, much of the treatment information for individuals
with the condition focuses on prophylactic measures that can be taken to decrease the burden of
disease on the individual. Generally, these measures are focused on preventing xenobiotic and
infectious insult to the lungs or liver, and healthy lifestyle choices. Ultimately, the aim is to
avoid a pro-inflammatory environment.

Smoking is a major cause of inflammation in the lungs, increasing host damage due to AATD,
and as such, is a major focus of the ADMAPP. This study found that ADMAPP adherent
individuals were far less likely to be active smokers, which is clinically significant (Table 5). In
addition, these individuals were more likely to be vaccinated for the flu in the past year, hepatitis
A, hepatitis B, which can be more serious in individuals with AATD, and recommended
vaccinations in the BFRG. Pneumonia vaccination rates were also significantly increased in the
adherent population prior to adjustment, but were not statistically significant in the logistic
regression model. Taken together these results are encouraging and suggest that the ADMAPP
adherent individuals are more likely to take an active effort in reducing the chances aggravating
their condition.

Perceived Health and Fitness
A number of questions on the survey dealt with the subject’s perception of their general health
and fitness as well as their exercise habits. The initial comparisons (Table 4) suggested several
instances of distinction between the two populations. Adjustment for covariates showed
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perceived fitness and exercise habits as being the only two statistically significant differences.
Like the other results presented, these conclusions should also be carefully interpreted.

For the perceived fitness question, the comparison was between individuals who answered “out
of shape” and those who answered any of the other options (“getting fit”, “pretty fit”, “very fit”).
These, like many of the other questions, have subjective answers that are relative to the observer,
meaning one person’s definition of “pretty fit” could be another person’s definition of “out of
shape.” This question may also be influenced by what can be referred to as “wishful thinking,”
meaning reporting may be based on what makes the individual feel better as opposed to reality.

While the ADMAPP adherent population was also found to be more likely to exercise, caution
should also be used when correlating the two questions. The exercise observation was a
combination of answers, similar to the perceived fitness question. Originally, study participants
were given the option of choosing no exercise or four additional options that included various
locations and regularity of exercise. These answers were combined so that any answer besides no
exercise, was coded as a yes. For the purposes of this study, it was decided that the regularity of
the exercise or location were not imperative to final interpretation, but the effort of exercise was.

Even with these limitations, the conclusion that ADMAPP adherent individuals are more likely
to exercise and have a positive image of their fitness remains fairly strong. It was not surprising
to not see a corresponding change in BMI or perceived weight. Significant changes in weight
would be the result of long term changes to multiple aspects of a person’s lifestyle. Considering
the lack of temporality of this data, it is impossible to state how long people have been involved
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in the program and therefore the impact of the program on that aspect may just not be visible at
the time of the survey.

The lack of differences between the perceived health of the total populations was equally
unsurprising. Health is an encompassing term and can mean many things to different people.
Without the explicitly stating in the question was aspects of health the questionnaire was
referring to (e.g., mental health, physical health, conditions unrelated to AATD), a statistically
significant difference would be difficult to interpret in the proper context.

Limitations
There are several important limitations of this study that should be considered along with the
results. First, all of the information, including the medical history, was collected via a self-report
questionnaire which brings into question the validity of the information provided. The self-report
nature of the study brings in recall bias (how accurate a person was able to remember
information), reporting bias (selective revealing or suppressing of information by the
participant), as well as a degree of social desirability bias (participants providing answers that
they think are correct or desired). The data also lacked a longitudinal component, meaning the
associations presented cannot be used to infer causality. In addition to this, there was also a
significant proportion of missing data and nonsensical entries, which are discussed in the
methodology section. The proportion of missing entries for the question concerning ADMAPP
compliance was 25.72%, meaning our results may under- or overestimate the true results.
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Conclusions
While missing observations continue to be a limitation of this study, the large sample size and
observations about the missing population alleviate some of the concerns about the missing
information. As this study indicates an association between ADMAPP adherence several
preventive outcomes, future studies need to be conducted using longitudinal data on this
population to determine if this relationship is causal. Ultimately, The results of this study display
the positive impact the ADMAPP can have on individuals with AATD. Individuals who selfreported their percent adherence to the program as being nonzero were more likely to be
informed about their condition and taking preventive measures, such as smoking cessation,
getting vaccinated for conditions that could magnify the effects of AATD, and increases in selfreported exercise.

26

Acknowledgements
I would like to express my gratitude to Dr. Mannino helping me choose a capstone project,
providing the data for the project, and offering advice throughout the entire project.

In addition, this project would not have gone as smoothly as it did without the help of Radmila
Choate who was always available to answer my questions about the data set or offer advice on
how to proceed.

I would also like to thank all of my coworkers in the Hennig laboratory, especially Jennifer
Moore, Dr. Michael Petriello, and Dr. Bernhard Hennig, for encouraging me to pursue an MPH,
as well as providing the financial support to do so.

Finally, I would like to thank Dr. Chesnut who has been a constant source of inspiration and
motivation throughout my time in the MPH program.

27

Additional Tables
Table 2. Covariates determined to be significant for each outcome
Age

Sex

Disease Knowledge and Treatment
Comfort with disease knowledge (Comfortable vs not comfortable)
Have read any part of BFRG (Yes vs No)
Use augmentation therapy (Yes vs No)

Y

Exacerbating and Prophylactic Factors
Still smoking (Yes vs No)
Drinker (Yes vs No)
Vaccinations
Pneumonia in last 6 years (Yes vs No)
Flu vaccine in last year (Yes vs No)
Hepatitis A (Yes vs No)
Hepatitis B (Yes vs No)
Health and Health Perception
Exercise (Yes vs No)
BMI
(Normal vs Overweight/Obese)
(Normal vs Underweight)
Perceived weight
(About Right vs Underweight)
(About Right vs Overweight)
Perceived fitness (Pretty fit/Getting fit/Very fit vs Out of Shape)
Perceived health (Good/Excellent vs Poor/Fair)
Health care provider visits
Primary care (> 1 visit vs 0 visits)
Lung specialist (> 1 visit vs 0 visits)
Liver specialist (> 1 visit vs 0 visits)
Other MD (> 1 visit vs 0 visits)
Emergency services utilization over past year
Hospital admittance (Yes vs No)
ICU admittance (Yes vs No)
ER (Yes vs No)

Y
Y

Y
Y
Y
Y
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Y

Y

Y

Y

Y
Y

Y

Y
Y
Y
Y

Y
Y
Y
Y

Y
Y

Y

Y

Y

Y

Y
Y

Y
Y
Y

Y
Y
Y

Y
91.7%

Y
70.8%

Y

Y

Y
Y
Y
Y

Y
Y

Y
83.3%

Y
Y

Y
Y

Y
Y
Y

Unscheduled MD visit (Yes vs No)
Percent significant

Y
Y

Y

Y

Y
Y
Y
Y

CCI

Y

Y

Y
Y
Y
Y

Income

37.5%

Table 3. Descriptive characteristics and statistics of the study population
Total Population
n=4,747
# (%)
Sex
Male
Female
Missing
Age (Mean + SD)
Marital status
Married
Single
Missing
Race
White
Non-White
Missing
Income
<$20,000
$20,000-$40,000
$40,000-$$60,000
$60,000-$80,000
$80,000-$100,000
>$100,000
Missing
AATD variant
PI*ZZ
PI*MZ
PI*SZ
PI*ZNull
PI*NullNull
Other
Unknown
Missing
Charlson Comorbidity Index (Mean + SD)
0
1
2
3
4
5
>6
Diagnosis prompt
Early onset lung disease
Yes
No
Missing
Emphysema
Yes
No
Missing
Uncontrolled asthma
Yes
No
Missing
Screening because relative has
Yes
No
Missing
Chronic bronchitis
Yes
No
Missing
Bronchiectasis
Yes
No
Missing
COPD
Yes
No
Missing
Cirrhosis
Yes
No
Missing

Non-Adherent
ADMAPP Users
n=1,921
# (%)

Adherent
ADMAPP Users
n=1.605
# (%)

2397 (50.50)
2135 (44.98)
215 (4.53)
56.67 + 11.76

1,026 (53.41)
873 (45.45)
22 (1.15)
56.34 + 12.19

806 (50.22)
780 (48.60)
19 (1.18)
56.96 + 11.22

2,787 (58.71)
1,640 (34.55)
320 (6.74)

1,141 (59.40)
715 (37.22)
65 (3.38)

1,042 (64.92)
531 (33.08)
32 (1.99)

4,399 (92.67)
107 (2.25)
241 (5.08)

1,825 (95.00)
61 (3.18)
35 (1.82)

1,563 (97.38)
24 (1.50)
18 (1.12)

1,150 (33.55)
910 (26.55)
572 (16.69)
341 (9.95)
191 (5.57)
264 (7.70)
1,319

564 (35.97)
414 (26.40)
267 (17.03)
147 (9.38)
75 (4.78)
101 (6.44)
353

371 (28.06)
361 (27.31)
234 (17.70)
147 (11.12)
84 (6.35)
125 (9.46)
283

2,507 (52.81)
522 (11.00)
323 (6.80)
33 (0.70)
14 (0.29)
162 (3.41)
769 (16.20)
417 (8.78)
0.77 + 1.28
3004 (63.28)
725 (15.27)
567 (11.94)
218 (4.59)
113 (2.38)
53 (1.12)
67 (1.41)

1,036 (53.93)
196 (10.20)
110 (5.73)
13 (0.68)
7 (0.36)
54 (2.81)
397 (20.67)
108 (5.62)
0.78 + 1.29
1,200 (62.47)
308 (16.03)
231 (12.02)
84 (4.37)
48 (2.50)
20 (1.04)
30 (1.56)

1,022 (63.68)
140 (8.72)
94 (5.86)
13 (0.81)
5 (0.31)
55 (3.43)
227 (14.14)
49 (3.05)
0.76 + 1.27
1,017 (63.36)
240 (14.95)
196 (12.21)
75 (4.67)
36 (2.24)
20 (1.25)
21 (1.31)

1,083 (22.81)
3,496 (73.65)
168 (3.54)

497 (25.87)
1,409 (73.35)
15 (0.78)

435 (27.10)
1,162 (72.40)
8 (0.50)

1,127 (23.74)
3,452 (72.72)
168 (3.54)

471 (24.52)
1,435 (74.70)
15 (0.078)

390 (24.30)
1,207 (75.20)
8 (0.50)

593 (12.49)
3,986 (83.97)
168 (3.54)

235 (12.23)
1,671 (86.99)
15 (0.78)

220 (13.71)
1,377 (85.79)
8 (0.50)

666 (14.03)
3,913 (82.43)
168 (3.54)

286 (14.89)
1,620 (84.33)
15 (0.78)

233 (14.52)
1,364 (84.98)
8 (0.50)

672 (14.16)
3,907 (82.30)
168 (3.54)

272 (14.16)
1,634 (85.06)
15 (0.78)

262 (16.32)
1,335 (83.18)
8 (0.50)

101 (2.13)
4,477 (94.31)
169 (3.56)

34 (1.77)
1,872 (97.45)
15 (0.78)

42 (2.62)
1,555 (96.88)
8 (0.50)

1,145 (24.12)
3,434 (72.34)
168 (3.54)

447 (23.27)
1,459 (75.95)
15 (0.78)

359 (22.37)
1,238 (77.13)
8 (0.50)

40 (0.84)
4,538 (95.60)
169 (3.56)

12 (0.62)
1,894 (98.59)
15 (0.78)

11 (0.69)
1,586 (98.82)
8 (0.50)

P-Values
0.059

0.117
0.004

Missing
n=1,221
# (%)
565 (46.27)
482 (39.48)
174 (14.25)
56.82 + 11.77
604 (49.47)
394 (32.27)
223 (18.26)

<0.001
1,011 (82.80)
22 (1.80)
188 (15.40)
<0.001
215 (39.96)
135 (25.09)
71 (13.20)
47 (8.74)
32 (5.95)
38 (7.06)
683
<0.001

0.760
0.927

449 (36.77)
186 (15.23)
119 (9.75)
7 (0.57)
2 (0.16)
53 (4.34)
145 (11.88)
260 (21.29)
0.75 + 1.27
787 (64.46)
177 (14.50)
140 (11.47)
59 (4.83)
29 (2.38)
13 (1.06)
16 (1.31)

0.438
151 (12.37)
925 (75.76)
145 (11.88)
0.842
266 (21.79)
810 (66.34)
145 (11.88)
0.205
138 (11.30)
938 (76.82)
145 (11.88)
0.730
147 (12.04)
929 (76.09)
145 (11.88)
0.080
138 (11.30)
938 (76.82)
145 (11.88)
0.087
25 (2.05)
1,050 (86.00)
146 (11.96)
0.496
339 (27.76)
737 (60.36)
145 (11.88)
0.829
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17 (1.39)
1,058 (86.65)
146 (11.96)

Table 4. Descriptive characteristics and statistics for outcome variables of interest

Disease Knowledge/Treatment
Comfort with disease knowledge
Not comfortable
Somewhat comfortable
Comfortable
Missing
Read any part of BFRG
Yes
No
Missing
Use augmentation therapy
Yes
No
Missing
Exacerbating and Preventive Factors
Smoking status
Never smoked
Have smoked
Missing
Still smoking
Yes
No
Missing
Drinking habits
Don’t drink
Drink
Missing
Weekly Drinks (Mean + SD)
Vaccinations
Pneumonia in last 6 years
Yes
No
Missing
Flu vaccine in last year
Yes
No
Missing
Hepatitis A
Yes
No
Missing
Hepatitis B
Yes
No
Missing
General Health Information
Body mass index (BMI)
Underweight
Normal
Overweight
Obese
Missing
Perceived weight
Underweight
About right
Overweight
Missing
Perceived fitness
Out of shape
Pretty fit
Getting fit
Very fit
Missing
Perceived Health
Poor
Fair
Good
Excellent
Missing
Exercise Habits
Exercise

Total
Population
n=4,747
# (%)

Non-Adherent
ADMAPP Users
n=1,921
# (%)

Adherent
ADMAPP Users
n=1.605
# (%)

268 (5.65)
2,109 (44.43)
2,114 (44.53)
256 (5.39)

147 (7.65)
960 (49.97)
782 (40.71)
32 (1.67)

36 (2.24)
574 (35.76)
974 (60.69)
21 (1.31)

1,886 (39.73)
2,180 (45.92)
681 (14.35)

518 (26.97)
1,361 (70.85)
42 (2.19)

1,126 (70.16)
461 (28.72)
18 (1.12)

3,750 (79.00)
383 (8.07)
614 (12.93)

1,679 (87.40)
190 (9.89)
52 (2.71)

1,500 (93.46)
83 (5.17)
22 (1.37)

1,022 (21.53)
3,095 (65.20)
630 (13.27)

463 (24.10)
1,415 (73.66)
43 (2.24)

398 (24.80)
1,196 (74.52)
11 (0.69)

185 (5.98)
2,893 (93.47)
17 (0.55)

107 (5.98)
1,295 (91.52)
13 (0.92)

38 (3.18)
1,157 (96.74)
1 (0.08)

2,340 (49.29)
1,716 (36.15)
691 (14.56)
5.52 + 6.69

1,093 (56.90)
757 (39.41)
71 (3.70)
5.79 + 7.07

842 (52.46)
727 (45.30)
36 (2.24)
5.50 + 6.55

3,488 (73.48)
529 (11.14)
730 (15.38)

1,586 (82.56)
255 (13.27)
80 (4.16)

1,391 (86.67)
174 (10.84)
40 (2.49)

3,522 (74.19)
574 (12.09)
651 (13.71)

1,592 (82.87)
285 (14.84)
44 (2.29)

1,409 (87.79)
176 (10.97)
20 (1.25)

1,578 (33.24)
1,835 (38.66)
1,334 (28.10)

677 (35.24)
864 (44.98)
380 (19.78)

733 (45.67)
620 (38.63)
252 (15.70)

2,225 (46.87)
1,430 (30.12)
1,092 (23.00)

957 (49.82)
681 (35.45)
283 (14.73)

1,046 (65.17)
427 (26.60)
132 (8.22)

212 (4.47)
1,553 (32.72)
1,249 (26.31)
1,304 (21.78)
699 (14.73)

91 (4.74)
655 (34.10)
515 (26.81)
443 (23.06)
217 (11.30)

76 (4.74)
580 (36.14)
439 (27.35)
328 (20.44)
182 (11.34)

482 (10.15)
1,605 (33.81)
2,009 (42.32)
651 (13.71)

225 (11.71)
716 (37.27)
930 (48.41)
50 (2.60)

184 (11.46)
665 (41.43)
736 (45.86)
20 (1.25)

1,967 (41.44)
1,205 (25.38)
781 (16.45)
115 (2.42)
679 (14.30)

982 (51.12)
502 (26.13)
323 (16.81)
45 (2.34)
69 (3.59)

632 (39.38)
531 (33.08)
351 (21.87)
61 (3.80)
30 (1.87)

781 (16.45)
1,745 (36.76)
1,407 (29.64)
152 (3.20)
662 (13.95)

378 (19.68)
826 (43.00)
601 (31.29)
58 (3.02)
58 (3.02)

273 (17.01)
646 (40.25)
589 (36.70)
74 (4.61)
23 (1.43)

2,720 (57.30)

1,103 (57.42)

1,192 (74.27)

P-Values

Missing
n=1,221
# (%)

<0.001
85 (6.96)
575 (47.09)
358 (29.32)
203 (16.63)
<0.001
242 (19.82)
358 (29.32)
621 (50.86)
<0.001
571 (46.76)
110 (9.01)
540 (44.23)

0.831
161 (13.19)
484 (39.64)
576 (47.17)
<0.001
40 (8.26)
441 (91.12)
3 (0.62)
0.001

0.416

405 (33.17)
232 (19.00)
584 (47.83)
4.72 + 5.77

0.017
511 (41.85)
100 (8.19)
610 (49.96)
<0.001
521 (42.67)
113 (9.25)
587 (48.08)
<0.001
168 (13.76)
351 (28.75)
702 (57.49)
<0.001
222 (18.18)
322 (26.37)
677 (55.45)

0.274
45 (3.69)
318 (26.04)
295 (24.16)
263 (21.54)
300 (24.57)
0.084
73 (5.98)
224 (18.35)
343 (28.09)
581 (47.58)
<0.001
353 (28.91)
172 (14.09)
107 (8.76)
9 (0.74)
580 (47.50)
<0.001
130 (10.65)
273 (22.36)
217 (17.77)
20 (1.64)
581 (47.58)
<0.001

30

425 (34.81)

Don’t exercise
Missing
Health Provider Visits
(Mean + SD), past year
Primary care
Lung specialist
Liver specialist
Other MD
Emergency Service Visits
(Mean + SD), past year
Hospital admittance
Intensive Care Unit admittance
Emergency room
Unscheduled MD visit

1,206 (25.41)
821 (17.30)

661 (34.41)
157 (8.17)

323 (20.12)
90 (5.61)

3.30 + 2.00
3.00 + 1.75
0.19 + 0.79
1.76 + 2.08

3.32 + 2.05
3.01 + 1.74
0.17 + 0.71
1.66 + 2.08

3.13 + 1.96
2.94 + 1.76
0.20 + 0.81
1.81 + 2.06

0.006
0.280
0.240
0.048

3.53 + 1.94
3.04 + 1.76
0.24 + 0.88
1.87 + 2.11

0.70 + 1.30
0.13 + 0.50
0.63 + 1.27
0.98 + 1.64

0.72 + 1.35
0.13 + 0.53
0.67 + 1.32
0.91 + 1.58

0.63 + 1.21
0.12 + 0.45
0.59 + 1.19
1.03 + 1.66

0.046
0.549
0.061
0.032

0.76 + 1.34
0.13 + 0.50
0.65 + 1.31
1.01 + 1.74
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222 (18.18)
574 (47.01)

Table 5. Comparison of outcome variables between ADMAPP adherent to non-adherent populations
using logistic regression
Disease Knowledge and Treatment
Comfort with disease knowledge (Comfortable vs not comfortable)
Have read any part of BFRG (Yes vs No)
Use augmentation therapy (Yes vs No)
Exacerbating and Prophylactic Factors
Still smoking (Yes vs No)
Drinker (Yes vs No)
Vaccinations
Pneumonia in last 6 years (Yes vs No)
Flu vaccine in last year (Yes vs No)
Hepatitis A (Yes vs No)
Hepatitis B (Yes vs No)
Health and Health Perception
Exercise (Yes vs No)
BMI
(Normal vs Overweight/Obese)
(Normal vs Underweight)
Perceived weight
(About Right vs Underweight)
(About Right vs Overweight)
Perceived fitness (Pretty fit/Getting fit/Very fit vs Out of Shape)
Perceived health (Good/Excellent vs Poor/Fair)
Health care provider visits
Primary care (> 1 visit vs 0 visits)
Lung specialist (> 1 visit vs 0 visits)
Liver specialist (> 1 visit vs 0 visits)
Other MD (> 1 visit vs 0 visits)
Emergency services utilization over past year
Hospital admittance (Yes vs No)
ICU admittance (Yes vs No)
ER (Yes vs No)
Unscheduled MD visit (Yes vs No)
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Crude Odds ratio
(95% CI)

Adjusted Odds Ratio
(95% CI)

5.09 (3.49-7.41)
6.42 (5.53-7.44)
2.05 (1.57-2.67)

4.95 (3.24-7.57)
6.44 (5.45-7.62)
2.08 (1.53-2.82)

0.40 (0.27-0.58)
1.25 (1.09-1.43)

0.47 (0.31-0.70)
1.12 (0.96-1.31)

1.29 (1.05-1.58)
1.43 (1.17-1.75)
1.51 (1.30-1.74)
1.74 (1.50-2.02)

1.14 (0.90-1.44)
1.34 (1.08-1.68)
1.41 (1.20-1.66)
1.62 (1.37-1.91)

2.21 (1.89-2.59)

2.07 (1.74-2.47)

1.11 (0.96-1.28)
1.06 (0.77-1.47)

1.04 (0.88-1.23)
0.99 (0.68-1.44)

1.14 (0.91-1.42)
1.17 (1.02-1.35)
1.68 (1.47-1.93)
1.32 (1.15-1.51)

1.03 (0.80-1.33)
1.12 (0.95-1.31)
1.66 (1.43-1.94)
1.16 (0.98-1.36)

1.15 (0.91-1.46)
1.01 (0.75-1.36)
1.13 (0.88-1.45)
1.29 (1.12-1.47)

1.22 (0.94-1.60)
1.07 (0.77-1.48)
1.13 (0.85-1.50)
1.28 (1.10-1.50)

0.89 (0.78-1.03)
1.06 (0.84-1.33)
0.89 (0.77-1.03)
1.16 (1.01-1.33)

0.94 (0.80-1.11)
1.15 (0.89-1.50)
1.00 (0.84-1.18)
1.27 (1.08-1.48)

Table 6. Results of testing for for missing ADMAPP adherence data

Sex
Male
Female
Missing
Marital status
Married
Single
Missing
Race
White
Non-White
Missing
Income
<$20,000
$20,000-$40,000
$40,000-$$60,000
$60,000-$80,000
$80,000-$100,000
>$100,000
Missing
Comfort with disease knowledge
Not comfortable
Somewhat comfortable
Comfortable
Missing
Read any part of BFRG
Yes
No
Missing
Pneumonia vaccine in last 6 years
Yes
No
Missing
Flu vaccine in last year
Yes
No
Missing
Hepatitis A vaccine
Yes
No
Missing
Hepatitis B vaccine
Yes
No
Missing
Body mass index (BMI)
Underweight
Normal
Overweight
Obese
Missing
Perceived weight
Underweight
About right
Overweight
Missing
Perceived fitness
Out of shape
Pretty fit
Getting fit
Very fit
Missing
Perceived Health
Poor
Fair
Good
Excellent
Missing
Exercise Habits
Exercise
Don’t exercise
Missing

Have Information on
ADMAPP Adherence
n=3,526
# (%)

Missing Information on
ADMAPP Adherence
n=1,221
# (%)

1,832 (51.96)
1,653 (46.88)
41 (1.16)

565 (46.27)
482 (39.48)
174 (14.25)

2,183 (61.91)
1,246 (35.34)
97 (2.75)

604 (49.47)
394 (32.27)
253 (20.72)

3,388 (96.09)
85 (2.41)
53 (1.50)

1,011 (82.80)
22 (1.80)
188 (15.40)

935 (26.52)
775 (21.98)
501 (14.21)
294 (8.34)
159 (4.51)
226 (6.41)
636 (18.04)

215 (17.61)
135 (11.06)
71 (5.81)
47 (3.85)
32 (2.62)
38 (3.11)
683 (55.94)

183 (5.19)
1,534 (43.51)
1,756 (49.80)
53 (1.50)

85 (6.96)
575 (47.09)
358 (29.32)
203 (16.63)

1,644 (46.63)
1,822 (51.67)
60 (1.70)

242 (19.82)
358 (29.32)
621 (50.86)

2,977 (84.43)
429 (12.17)
120 (3.40)

511 (41.85)
100 (8.19)
610 (49.96)

3,001 (85.11)
461 (13.07)
64 (1.82)

521 (42.67)
113 (9.25)
587 (48.08)

1,410 (39.99)
1,484 (42.09)
632 (17.92)

168 (13.76)
351 (28.75)
702 (57.49)

2,003 (56.81)
1,108 (31.42)
415 (11.77)

222 (18.18)
322 (26.37)
677 (55.45)

167 (4.74)
1,235 (35.03)
954 (27.06)
771 (21.87)
399 (11.32)

45 (3.69)
318 (26.04)
295 (24.16)
263 (21.54)
300 (24.57)

409 (11.60)
1,381 (39.17)
1,666 (47.25)
70 (1.99)

73 (5.98)
224 (18.35)
343 (28.09)
581 (47.58)

1,614 (45.77)
1,033 (29.30)
674 (19.12)
106 (3.01)
99 (2.81)

353 (28.91)
172 (14.09)
107 (8.76)
9 (0.74)
580 (47.50)

651 (18.46)
1,472 (41.75)
1,190 (33.75)
132 (3.74)
81 (2.30)

130 (10.65)
273 (22.36)
217 (17.77)
20 (1.64)
581 (47.58)

2,295 (65.09)
984 (27.91)
247 (7.01)

425 (34.81)
222 (18.18)
574 (47.01)

P-value
0.428

0.705

0.550

0.013

<0.001

0.001

0.011

0.003

<0.001

<0.001

0.022

0.036

<0.001

0.716

0.030

33

Additional Figures

Figure 2. Choropleth map showing state of residence of study participants
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